本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection, a recombinant anti-IGF-1R antibody), Limertinib (EGFR TKI), Dupert® (fulzerasib, KRAS G12C inhibitor), DOVBLERON® (taletrectinib, ROS1 inhibitor), Retsevmo® (selpercatinib, RET inhibitor), and Jaypirca® (pirtobrutinib, BTK inhibitor). The updated NRDL will be officially effective from January 1, 2026. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are pleased with the NRDL inclusion of our seven innovative therapies this year. These therapies cover key disease areas that pose substantial public health challenges in China—particularly oncology (including lung, liver, gastric, esophageal, gynecological cancers, and hematological malignancies) as well as cardiovascular and metabolic (CVM) diseases. Their inclusion will help broaden patients' access to and enhance their affordability of these medications, ultimately benefiting more individuals and families across the country. As a company with the mission of 'empowering patients worldwide with affordable, high-quality biopharmaceuticals', Innovent continues to invest in pioneering treatments across oncology, CVM, autoimmune and ophthalmology—areas of significant societal need. We remain committed to our patient-centered approach, leveraging our innovation and product capabilities to further improve drug affordability and accessibility, so that high-quality medicines can reach and benefit more patients and their families as soon as possible. We are proud to contribute to better care for our patients." TYVYT® (sintilimab injection) TYVYT® (sintilimab injection) is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. In China, sintilimab has been approved for eight indications and two more NDAs are under review by the NMPA, including squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma[i]. In the updated NRDL, the eighth indication of TYVYT®(sintilimab injection) is newly included, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. This new indication addresses a critical gap in treatments available for advanced endometrial cancer patients with limited responses to traditional therapies. SYCUME® (teprotumumab N01 injection) SYCUME® (teprotumumab N01 injection) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody developed by Innovent. SYCUME® blocks the activation of IGF-1R signaling pathway, consequently improving clinical manifestations such as proptosis, inflammation and diplopia, thus enhancing quality of life in patients with thyroid eye disease (TED)[ii]. In the updated NRDL, SYCUME®(teprotumumab N01 injection) is newly listed for moderate-to-severe thyroid eye disease. SYCUME®(teprotumumab N01 injection) is China's first approved IGF-1R antibody drug, and this groundbreaking non-invasive therapy redefines the standard of care and serves the unmet needs for thyroid eye disease over past 70 years in China. The NRDL inclusion will bring this world-class novel treatment option to Chinese patients with thyroid eye disease and significantly enhance patient accessibility and affordability. Limertinib Limertinib is a third-generation EGFR TKI in collaboration with ASK Pharm, and Innovent holds exclusive commercialization rights in Mainland China.[iii] In the updated NRDL, limertinib is newly listed for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), who have previously experienced disease progression during or after treatment with EGFR TKI; and 2) the first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations. Limertinib incorporates a unique naphthylamine group structure, which endows it with enhanced lipophilicity. This property ensures effective drug penetrate across the blood-brain barrier (BBB), thereby significantly reducing the risk of disease progression—specifically, the risk of disease progression in patients with brain metastases and the risk of intracranial disease progression. The NRDL inclusion of limertinib will provide a more effective treatment option for NSCLC patients with EGFR mutations. Dupert® (fulzerasib) Dupert® (fulzerasib) is a novel KRAS G12C inhibitor in collaboration with GenFleet Therapeutics, and Innovent holds exclusive development and commercialization rights in Greater China.[iv] In the updated NRDL, Dupert®(fulzerasib) is newly listed for the treatment of advanced NSCLC adult patients harboring KRAS G12C mutation who have received at least one systemic therapy. The NRDL inclusion of Dupert®(fulzerasib) will provide a novel targeted therapy benefiting NSCLC patients harboring KRAS G12C mutation. DOVBLERON® (taletrectinib) DOVBLERON® (taletrectinib) is a novel next-generation ROS1 TKI in collaboration with Nuvation Bio China, a Nuvation Bio (NYSE: NUVB) Company, and Innovent holds exclusive commercialization rights in Greater China.[v] In the updated NRDL, DOVBLERON® (taletrectinib) is newly listed for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The NRDL inclusion of DOVBLERON® (taletrectinib) will provide a potentially best-in-class therapy benefiting patients with locally advanced ROS1-positive NSCLC. Retsevmo® (selpercatinib) Retsevmo® (selpercatinib) is a selective and potent rearranged during transfection (RET) kinase inhibitor developed by Eli Lilly and Company and solely commercialized in Mainland China by Innovent.[vi] In the updated NRDL, Retsevmo® (selpercatinib) is newly listed for the treatment of: 1) adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, 2) adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, and 3) adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory. Retsevmo® (selpercatinib) is the first RET inhibitor approved globally and its NRDL inclusion will bring an innovative therapy for NSCLC and thyroid cancer patients with a RET alteration. Jaypirca® (pirtobrutinib) Jaypirca® (pirtobrutinib) is a non-covalent (reversible) BTK inhibitor developed by Eli Lilly and Company and solely commercialized in Mainland China by Innovent. Jaypirca® (pirtobrutinib) is the first and only non-covalent (reversible) BTK inhibitor approved in the world.[vii] In the updated NRDL, Jaypirca® is newly listed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two types of systemic therapy, including a BTK inhibitor. Its NRDL inclusion will benefit heavily-treated MCL patients that previously received the treatment of a BTK inhibitor, addressing their unmet needs and further enhancing Jaypirca's affordability for those patients. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statements: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Ramucirumab（Cyramza）, Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. [i] TYVYT® (sintilimab injection) Product Insert [ii] SYCUME® (teprotumumab N01 injection) Product Insert [iii] Limertinib Product Insert [iv] Dupert® (fulzerasib) Product Insert [v] DOVBLERON® (taletrectinib) Product Insert [vi] Retsevmo® (selpercatinib) Product Insert [vii] Jaypirca® (pirtobrutinib) Product Insert
韓國首爾2025年12月7日 /美通社/ -- DWMaterials以其新一代電磁分離器技術作為增長基石，加速向二次電池和先進材料行業擴張。 憑借在熱交換器和反應器工程領域超過30年的技術積累，該公司正在從傳統設備製造邁向新賽道，鞏固其作為助力客戶提升質量競爭力的技術合作夥伴的地位。 在二次電池領域，異物去除技術是直接關係到電芯質量和安全的關鍵因素。憑借其專有的高純度消磁與分離技術，DWMaterials逐漸成為新一代電池生產線的重要設備供應商。 公司發言人表示：「我們不僅僅是設備供應商，更是值得信賴的合作夥伴，可以保障客戶的可靠性和質量。DWMaterials將繼續擴大其在全球材料行業的業務版圖。」
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- DWMaterials is accelerating its expansion into the secondary battery and advanced materials industries, leveraging its next-generation electromagnetic separator technology as a foundation for growth. With over 30 years of accumulated expertise in heat exchanger and reactor engineering, the company is evolving beyond traditional equipment manufacturing to strengthen its position as a technology partner that enhances customers' quality competitiveness. In the secondary battery sector, foreign substance removal technology is a crucial factor directly linked to cell quality and safety. Equipped with its proprietary high-purity demagnetization and separation technology, DWMaterials is emerging as a key equipment supplier for next-generation battery production lines. A company representative stated, "We are not merely an equipment supplier, but a trusted partner that guarantees our customers' reliability and quality," adding, "DWMaterials will continue to expand its footprint across the global materials industry."
香港2025年12月6日 /美通社/ -- 中國知名特色餐飲連鎖集團——廣州遇見小麵餐飲股份有限公司（簡稱「遇見小麵」或「公司」，股票代碼：2408.HK）今天正式在香港交易所主板上市，成為公開市場上首個中式麵館股。此次全球發售獲得機構投資者的踴躍參與，HHLR Advisors, Ltd.（「HHLRA」，高瓴集團旗下成員）、Hai Di Lao Holdings Pte. Ltd.（「海底撈」）、Dream'ee (Hong Kong) Open-ended Fund Company、香港晟盈投資有限公司（「晟盈投資」）、Zeta Wisdom OFC（「Zeta Fund」）作為基石投資者參與認購。 遇見小麵在香港聯合交易所正式掛牌上市 根據弗若斯特沙利文報告，按2024年商品交易總額(GMV)計，遇見小麵在川渝風味麵館中排名全國第一，在所有中式麵館經營者中位列第四。過去三年，公司業務拓展與財務表現卓越。收入從2022年的4.18億元飆升至2024年的11.54億元，年複合增長率達66.2%，遠超中國整體快餐市場增速。這一增長態勢延續至2025年上半年，期間遇見小麵實現收入7.03億元，同比增長33.8%，經調整淨利潤大幅增長131.56%至5218萬元，均創歷史新高。 遇見小麵於2014年在廣州創立，憑借清晰的戰略規劃和嚴謹的運營管理實現快速增長。其餐廳網絡從2022年初的133家門店，擴展至如今覆蓋中國大陸及香港22個城市的465家門店。另有115家新店正在籌備中，公司即將在年底前突破500家餐廳。值得一提的是，第500家門店將落戶新加坡，這既是該公司首家海外門店，也標誌著中國餐飲體繫向全球邁出重要的一步。 遇見小麵採用「直營+加盟」雙輪驅動的規模化商業模式。所有門店均依托集中化、標準化、數字化的管理系統運營，管理範疇覆蓋配方研發、集中採購、供應鏈管理、選址開店、門店建設、日常運營、員工培訓、營銷推廣及質量管控等全流程。該公司專注地道川渝風味，主打招牌紅碗豌雜面、金碗酸辣粉、抄手系列以及小鍋冒菜系列。每家餐廳通常提供30-40款菜品，並定期更新菜單，以此提升顧客用餐體驗，確保每次用餐都溫馨、親切且令人回味。 該公司還自主研發了全鏈路餐廳運營系統，覆蓋前後端工作流程，包括訂單管理、堂食外賣履約、排班調度、生產控制、採購、庫存管理、供應鏈協同、人才培養和績效考核等環節。 展望未來，此次IPO募集資金將用於加速公司多年擴張計劃，提升數字化與供應鏈實力，並推進其國際化戰略。遇見小麵計劃未來三年新開520至610家餐廳，且已開啟海外佈局。其首家海外門店將於2025年12月在新加坡開業，這標誌著中國餐飲體繫向全球市場推廣邁出關鍵一步，也將東南亞確立為新的增長引擎。 登陸港交所是遇見小麵發展歷程中的重要里程碑。在「中國小麵，全球遇見」願景的指引下，公司將持續加強數字化運營，優化供應鏈效率，為中國乃至全球消費者帶來高品質、高價值的中華美食。 欲瞭解更多關於遇見小麵的信息，請訪問：https://www.xiaonoodles.com/en
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- SURFIRAN CO LTD is emerging as a pioneer in Korea's gourmet food market by introducing saffron-based products and raising awareness of saffron—one of the world's top three gourmet treasures alongside caviar and truffles. Although saffron enjoys global prestige, it has remained relatively unknown in Korea. SURFIRAN CO LTD saw this as an opportunity and began importing top-grade saffron directly, transforming it into consumer-friendly formats that allow everyday enjoyment. With recent launches such as saffron pearl balsamic vinegar, the company is accelerating efforts to popularize saffron domestically. Beyond product development, SURFIRAN CO LTD is expanding the broader "saffron gourmet experience" through collaborations with chefs, culinary experts, and premium restaurants, helping saffron find a place in Korea's fine-dining scene. A company spokesperson stated, "Korea has never had a fully developed saffron culture. Our mission is to introduce the true flavor, aroma, and health benefits of saffron to a wider audience and lead the next wave of gourmet innovation."
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructure enables high-volume prosthetics manufacturing and exceptional capability in handling complex clinical cases. By combining state-of-the-art digital equipment with highly skilled dental technicians, the company's clinically integrated collaboration model maximizes both accuracy and efficiency in prosthetic production, strengthening trusted partnerships with dental clinics and hospitals nationwide. As a large-scale digital dental laboratory, Leaders Dental provides a wide range of services, including implant prosthetics, surgical guides, and digital dentistry support. Leveraging over a decade of comprehensive clinical data, the company enhances precision in prosthetic design and facilitates rapid communication between dentists and technicians through its cloud-based feedback platform. Its diagnostic solutions based on 3D patient data—developed in collaboration with ALL-CONEC—further validate Leaders Dental's clinical expertise and contribute to higher satisfaction in clinical settings. With a vision to become "the central hub of the digital dentistry ecosystem," Leaders Dental plans to strengthen and systematize its quality control (QC) processes, maximizing the benefits of its large-scale operations. A company representative stated, "Our expansive infrastructure and clinical expertise form the foundation of trust in Korea's dental laboratory sector," adding, "By upholding our clinically driven values and supporting the treatment capabilities of partner clinics, we aim to further elevate the global reputation of K-dental technology."
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
